Cambridge Investment Research Advisors, Inc. Coherus Bio Sciences, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 15,796 shares of CHRS stock, worth $11,689. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,796
Previous 19,585
19.35%
Holding current value
$11,689
Previous $34,000
52.94%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$8.37 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$7.7 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.25 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$2.11 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $57.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...